Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals (Nasdaq: AVDL), a biopharmaceutical company, has announced its participation in three major upcoming investor conferences in September 2025. The company will participate in fireside chat sessions at the 2025 Wells Fargo Healthcare Conference on September 5, the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10.
All presentations will be available via webcast on the company's investor relations website for 90 days following each conference.
Avadel Pharmaceuticals (Nasdaq: AVDL), società biofarmaceutica, ha annunciato la sua partecipazione a tre importanti conferenze per investitori previste a settembre 2025. L'azienda interverrà con sessioni 'fireside chat' al 2025 Wells Fargo Healthcare Conference il 5 settembre, al Morgan Stanley 23rd Annual Global Healthcare Conference il 9 settembre e all'H.C. Wainwright 27th Annual Global Investment Conference il 10 settembre.
Tutte le presentazioni saranno disponibili in webcast sul sito delle relazioni con gli investitori della società per 90 giorni dopo ciascuna conferenza.
Avadel Pharmaceuticals (Nasdaq: AVDL), una compañía biofarmacéutica, ha anunciado su participación en tres importantes conferencias para inversores que se celebrarán en septiembre de 2025. La compañía realizará sesiones tipo 'fireside chat' en el 2025 Wells Fargo Healthcare Conference el 5 de septiembre, en el Morgan Stanley 23rd Annual Global Healthcare Conference el 9 de septiembre y en el H.C. Wainwright 27th Annual Global Investment Conference el 10 de septiembre.
Todas las presentaciones estarán disponibles mediante webcast en la web de relaciones con inversores de la compañía durante 90 días tras cada conferencia.
Avadel Pharmaceuticals (Nasdaq: AVDL)는 바이오제약사로서 2025년 9월에 열리는 주요 투자자 컨퍼런스 세 곳에 참여한다고 발표했습니다. 회사는 9월 5일 2025 Wells Fargo Healthcare Conference, 9월 9일 Morgan Stanley 23rd Annual Global Healthcare Conference, 9월 10일 H.C. Wainwright 27th Annual Global Investment Conference에서 파이어사이드 채트(fireside chat) 세션에 참여합니다.
모든 발표 내용은 각 컨퍼런스 종료 후 90일 동안 회사의 투자자 관계 웹사이트를 통해 웨비캐스트로 제공됩니다.
Avadel Pharmaceuticals (Nasdaq: AVDL), une société biopharmaceutique, a annoncé sa participation à trois grandes conférences investisseurs prévues en septembre 2025. La société prendra part à des sessions 'fireside chat' lors du 2025 Wells Fargo Healthcare Conference le 5 septembre, du Morgan Stanley 23rd Annual Global Healthcare Conference le 9 septembre et du H.C. Wainwright 27th Annual Global Investment Conference le 10 septembre.
Toutes les présentations seront disponibles en webcast sur le site relations investisseurs de la société pendant 90 jours après chaque conférence.
Avadel Pharmaceuticals (Nasdaq: AVDL), ein biopharmazeutisches Unternehmen, hat seine Teilnahme an drei bedeutenden Investorenkonferenzen im September 2025 angekündigt. Das Unternehmen wird an Fireside-Chat-Sessions beim 2025 Wells Fargo Healthcare Conference am 5. September, beim Morgan Stanley 23rd Annual Global Healthcare Conference am 9. September und beim H.C. Wainwright 27th Annual Global Investment Conference am 10. September teilnehmen.
Alle Präsentationen werden für 90 Tage nach jeder Konferenz per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
- 2025 Wells Fargo Healthcare Conference: Fireside chat on Friday, September 5 at 11:00 a.m. ET.
- Morgan Stanley 23rd Annual Global Healthcare Conference: Fireside chat on Tuesday, September 9 at 1:05 p.m. ET.
- H.C. Wainwright 27th Annual Global Investment Conference: Fireside chat on Wednesday, September 10 at 9:30 a.m. ET.
A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.murtagh@precisionaq.com
(212) 698-8696
Media Contact:
Alyssa Ramirez
Real Chemistry
aramirez@realchemistry.com
